- Home
- HNVR vs ACRS Comparison
HNVR vs ACRS Comparison
Compare HNVR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- ACRS
- Stock Information
- Founded
- HNVR 2008
- ACRS 2012
- Country
- HNVR United States
- ACRS United States
- Employees
- HNVR N/A
- ACRS N/A
- Industry
- HNVR Commercial Banks
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- ACRS Health Care
- Exchange
- HNVR Nasdaq
- ACRS Nasdaq
- Market Cap
- HNVR 167.7M
- ACRS 165.7M
- IPO Year
- HNVR 2022
- ACRS 2015
- Fundamental
- Price
- HNVR $21.51
- ACRS $1.87
- Analyst Decision
- HNVR Buy
- ACRS Strong Buy
- Analyst Count
- HNVR 2
- ACRS 9
- Target Price
- HNVR $23.75
- ACRS $9.25
- AVG Volume (30 Days)
- HNVR 12.4K
- ACRS 1.5M
- Earning Date
- HNVR 07-23-2025
- ACRS 08-07-2025
- Dividend Yield
- HNVR 1.86%
- ACRS N/A
- EPS Growth
- HNVR N/A
- ACRS N/A
- EPS
- HNVR 1.53
- ACRS N/A
- Revenue
- HNVR $68,211,000.00
- ACRS $16,789,000.00
- Revenue This Year
- HNVR N/A
- ACRS N/A
- Revenue Next Year
- HNVR $13.97
- ACRS $8.11
- P/E Ratio
- HNVR $14.08
- ACRS N/A
- Revenue Growth
- HNVR 14.14
- ACRS N/A
- 52 Week Low
- HNVR $16.71
- ACRS $1.05
- 52 Week High
- HNVR $27.14
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- HNVR 46.65
- ACRS 75.14
- Support Level
- HNVR $20.88
- ACRS $1.58
- Resistance Level
- HNVR $22.40
- ACRS $1.77
- Average True Range (ATR)
- HNVR 0.57
- ACRS 0.11
- MACD
- HNVR 0.08
- ACRS 0.02
- Stochastic Oscillator
- HNVR 47.79
- ACRS 94.25
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.